Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition
Patent Information
- Application Number
- HK62026124908
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-05
- Filing Date
- 2026-06-16
- Publication Date
- 2026-09-11
Smart Images

Figure 00000022_0000 
Figure 00000023_0000 
Figure 00000024_0000
Abstract
Description
Abstract This invention relates to the use of lanilanol or its deuterated form or pharmaceutically acceptable salts for the treatment of visceral vasodilation in patients with liver disease.
Claims
Claims1. Lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof for use in the treatment of splanchnic vasodilatation in a patient with a liver condition.
2. Lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof for use of claim 1 , wherein the liver condition is cirrhosis, acute liver failure, acute- on-chronic liver failure, hepatopulmonary syndrome, hepatorenal syndrome, or hepatic encephalopathy.
3. Lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof for use of any one of claims 1 to 2, wherein the liver condition is cirrhosis, in particular decompensated cirrhosis.
4. Lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof for use of any one of claims 1 to 3, wherein lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof is administered at a daily dose of from about 5 mg to about 1 ,200 mg.
5. Lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof for use according to any one of claims 1 to 4, wherein the deuterated form of lanifibranor is a compound of formula (I):wherein at least one of the groups Ri to R7is a deuterium (D) atom and the other groups Ri to R7are hydrogen (H) atoms.
6. A pharmaceutical composition comprising a pharmaceutically effective amount of lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof for use in the treatment of splanchnic vasodilatation in a patient with a liver condition.
7. The pharmaceutical composition for use of claim 6, wherein the pharmaceutical composition is a solid dosage form, a semi-solid dosage form or a liquid dosage form, advantageously a solid dosage form.
8. The pharmaceutical composition for use of any one of claims 6 to 7, wherein the solid dosage form is a tablet, a capsule, a stick-pack, a sachet, a lozenge, a powder, a pill or a granule, advantageously a tablet, a capsule or a stick-pack.
9. The pharmaceutical composition for use of any one of claims 6 to 8, wherein the pharmaceutical composition comprises from 5 mg to 1 ,200 mg of lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof.
10. The pharmaceutical composition for use of claim 9, wherein the pharmaceutical composition comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 150 mg, at least 200 mg, at least 250 mg, at least 300 mg, at least 350 mg, at least 400 mg, at least 450 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, at least 850 mg, at least 900 mg, at least 950 mg, at least 1 ,000 mg, at least 1 ,050 mg, at least 1 ,100 mg, at least 1 ,150 mg, or 1 ,200 mg of lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof.11 . The pharmaceutical composition for use of any one of claims 6 to 10, wherein the pharmaceutical composition is administered via oral, parenteral or topical route.
12. A method of treating splanchnic vasodilatation in a patient with a liver condition, the method comprising administering lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof, or a pharmaceutical composition comprising lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof, to the patient.
13. The method of claim 12, wherein the liver condition is cirrhosis, acute liver failure, acute-on-chronic liver failure, hepatopulmonary syndrome, hepatorenal syndrome or hepatic encephalopathy.
14. The method of claim 13, wherein the liver condition is cirrhosis, in particular decompensated cirrhosis.
15. The method of any one of claim 12 to claim 14, wherein lanifibranor or a deuterated form thereof or a pharmaceutical acceptable salt thereof is administered at a daily dose of from about 5 mg to about 1 ,200 mg.
16. The method of any of claims 12 to 15, wherein the pharmaceutical composition is a solid dosage form.
17. The method of claim 16, wherein the solid dosage form is a tablet, a capsule or a stick-pack.
